abstract BACKGROUND AND OBJECTIVE: Many pediatric rheumatology patients are at increased risk of pneumococcal disease secondary to a deficient immune system and/or immunosuppressive medications. The goal of this study was to improve pneumococcal vaccination rates in this high-risk population.
rate increased from 8.9% to 28.4% (x 2 = 16.0, P , .001), and combined rate increased from 0% to 23.2% (x 2 = 25.2, P , .001). The improvement was sustained with shifts in the data for each vaccine and combined immunizations for final average rates of 60.9% for 13-valent pneumococcal conjugate vaccine, 39.2% for 23-valent pneumococcal polysaccharide vaccine, and 33.7% for combined.
CONCLUSIONS: Pneumococcal vaccination is an important part of the care for systemic lupus erythematosus patients and patients on immunosuppressive medications. Simple interventions through this quality improvement project led to a marked increase in pneumococcal vaccination rates in this vulnerable population.
Streptococcus pneumoniae is a leading cause of bacteremia, meningitis, pneumonia, sinusitis, and acute otitis media. 1 Many pediatric rheumatology patients are at increased risk of pneumococcal disease secondary to a deficient immune system and/or immunosuppressive medications. Infections can be a significant complication in certain rheumatic diseases that can lead to hospitalization and death. [2] [3] [4] [5] [6] [7] One retrospective review of patients with systemic lupus erythematosus (SLE) revealed infection was the second most common cause for hospitalization after a disease flare, with the most common type of infection leading to hospitalization being pneumonia. 2 Another study reviewed a cohort of 1000 patients with SLE from 7 European countries to assess frequency and cause of morbidity and mortality over a 10-year period from 1990 to 2000. 3 Twenty-five 12 The American Academy of Pediatrics subsequently endorsed these guidelines and recently generated a policy statement for pneumococcal immunization in children at high risk. 13, 14 This quality improvement project was conducted to increase pneumococcal vaccination rates in eligible pediatric rheumatology clinic patients. Our initial aim was to increase PCV13 rates to 30% after 4 months. However, our study continued after the initial 4 months because of positive responses and continued improvement.
METHODS

Vaccines
The CDC recommends PCV13 4 times during early childhood. 15 All eligible clinic patients who were in need of a pneumococcal vaccine were compiled into a weekly e-mail that was sent to all providers and nurses informing them of this information. The rheumatology clinic nurses then began placing reminders on clinic encounter forms, which is a paper that is generated for every visit encounter in all of our institution's clinics and passed on to the provider when the patient is ready to be seen. From the weekly e-mails, the nurses wrote "PCV13" or "PPSV23" on small pieces of brightly colored construction paper, which was stapled to clinic encounter forms the morning of the patient's visit. Clinic flow would include the providers discussing the vaccine with the patient and family, placing an order for the particular vaccine needed, and notifying the nurse if a vaccine should be administered. Pneumococcal vaccines were often administered in clinic, and nurses provided an educational document regarding the specific vaccine to the patient and family.
FIGURE 1
Control chart demonstrating percent of patients up to date on PCV13 out of total eligible clinic patients. Interventions are noted. A shift was present in the data resulting in an increased center line starting on May 13, 2013. Other special cause includes a trend and data point above the upper control limit.
FIGURE 2
Control chart demonstrating percent of patients up to date on PPSV23 out of total number of eligible clinic patients. Interventions are noted. A shift was present in the data resulting in an increased center line starting on July 8, 2013. Other special cause includes 3 data points above the upper control limit.
Another intervention included sending letters to out-of-state patients and/or patients who had no immunization record or an incomplete record in the Wisconsin Immunization Registry. The letter explained the need for a copy of the patient's immunization record to determine if a pneumococcal vaccine was indicated. In addition, updates of pneumococcal immunization rates were provided intermittently at division meetings or via e-mail.
Data Analysis
Chart reviews continued after initiation of interventions to determine PCV13 and PPSV23 rates.
Control charts with upper and lower control limits (3 SDs above and below the mean) were created to display vaccination rates over time for each vaccine and combined vaccines. Nonrandom distribution or special cause was assessed. Rules for special cause include the following: a shift (8 consecutive data points on 1 side of the center line), a trend (6 consecutive data points steadily increasing or decreasing), and a data point outside of the control limits. 17 The center line was adjusted and recalculated if a shift was present in the data. Control chart demonstrating percent of patients up to date with both PCV13 and PPSV23 out of total eligible clinic patients. Interventions are noted. A shift was present resulting in an increased center line starting on May 6, 2013. Other special cause includes a data point above the upper control limit.
FIGURE 4
Pneumococcal immunization algorithm. Please refer to the CDC for complete guidelines on a patient' s need for pneumococcal vaccines. 1 to 33.7% after a shift in the data. There were also data points above the upper control limits in each of the 3 charts.
DISCUSSION
This single-center quality improvement project to increase pneumococcal vaccination rates in eligible pediatric rheumatology clinic patients was a success that can serve as a model for other hospitals and divisions. Through simple quality improvement initiatives, our vaccination rates statistically increased over time and were sustained indicating a true change in practice. Although pediatric rheumatology patients make up a minority of patients seen in general pediatric offices and subspecialty clinics, the quality improvement interventions from this project can be extrapolated to any immunosuppressed patient or patient at high risk for pneumococcal disease. Key points to improve pneumococcal vaccination rates on the basis of our experience are highlighted in Table 2 .
Similar quality improvement studies in our specific population are lacking. However, a quality improvement project in adult rheumatology practices used a point-of-care paper reminder form to significantly increase the rate of pneumococcal vaccination in immunosuppressed patients. 18 An additional project used a 1-page vaccine questionnaire in clinic for patients to fill out to improve influenza and pneumococcal vaccination rates in immunosuppressed patients with inflammatory bowel disease. 19 There are no known articles describing pneumococcal vaccination rates in the pediatric rheumatology population, although preliminary data from our center revealed 25.3% of patients with childhood-onset SLE in a small cohort received the PPSV23. 20 In addition, 52.5% of immunocompromised adults and 60% to 69% of adults with SLE selfreported receipt of the PPSV23. [21] [22] [23] Direct comparison of these studies to our population cannot be done because the older age of some of the patients may have been the primary reason for getting the pneumococcal vaccine. Receipt of PCV13 was also not obtained in these studies.
Our results should be interpreted in the context of important limitations. First, due to having multiple interventions that overlap in time, it is difficult to determine causal relationship of any 1 of these initiatives to improvement. Also, having a single person at our center in charge of previsit planning and other initiatives was a limitation because work absences could lead to a brief lapse in continuation of quality improvement efforts. It is important to note our total population changed over time as new patients became eligible for the vaccines and others became ineligible if transitioned to an adult provider or if their immunosuppressive medication was discontinued. Therefore, the results may have differed if the denominator of eligible patients remained constant. Lastly, providers may have demonstrated quality improvement "fatigue" due to the prolonged nature of our project. To address this limitation, occasional discussion about our success and/or showing our control chart progress in increasing immunization rates was done via e-mail or at division meetings.
The initial increasing trend in PCV13 rates was likely due to mere discussion of this project and start of previsit planning. There were instances of special cause variation with data points above the upper control limits, but it was unclear what specifically caused this. PCV13 rates are higher than PPSV23 rates because this vaccine is a routine immunization of childhood and it is recommended first in the series of pneumococcal vaccines if the patient is naïve to both of them. Continued quality initiatives throughout the study period, in particular previsit planning and reminders to providers, likely contributed to the sustained improvement in vaccination rates. A plateau in vaccination rates for each pneumococcal immunization and combined immunization rate may have been due to change in patient population contributing to a different denominator of patients as described above. In addition, no new quality initiatives were implemented in the last several weeks of data collection. Furthermore, patients were not vaccinated due to lack of vaccination records, provider forgetting to discuss vaccinations, patient being acutely ill, patient/parent refusal, and family preference to get vaccine elsewhere.
To improve and maintain future performance, a team approach is highly recommended because relying on a single individual to do certain initiatives is not sustainable. However, a team leader or "champion" is essential for a project like this to continue. Further improvements in vaccination rates may be obtained if focus shifts to the patients and families as our initiatives were directed primarily to the providers. This may include sending letters to all eligible clinic patients and providing an educational document explaining the importance of pneumococcal vaccination as part of the care of their disease. In addition, visual reminders to both providers and patients in clinic rooms may be of benefit.
CONCLUSIONS
Pneumococcal vaccination is an important part of the care for patients with SLE and patients with other pediatric rheumatologic conditions on immunosuppressive medications. Simple quality interventions were performed, which evolved around provider education and reminders. This led to a marked and sustained increase in pneumococcal vaccination rate in this vulnerable population.
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